PTPRB_HUMAN » Receptor-type tyrosine-protein phosphatase beta

PTPRB_HUMAN » Receptor-type tyrosine-protein phosphatase beta
Magnify PTPRB_HUMAN » Receptor-type tyrosine-protein phosphatase betaEnlarged view of image
3D view in GLMol or JMol

gray dot

Download Coordinates

gray dot

Topology in Plasma membrane
Topologyextracellular side
cytoplasmic side
PTPRB_HUMAN » Receptor-type tyrosine-protein phosphatase beta » Protein-tyrosine phosphatase beta; R-PTP-beta; Vascular endothelial protein tyrosine phosphatase;VE-PTP;
Hydrophobic Thickness 27.6 ± 2.0 Å
Tilt Angle 0 ± 1°
ΔGtransfer -36.2 kcal/mol
ΔGfold -16.9 kcal/mol
Links UniProtKB, Pfam, Interpro, iHOP, STRING, HGNC, HMDB
Topology Out
TM Segments 1622-1644 (1619-1645)
Pathways

Adherens junction (KEGG)

PDB 2i5x (1662-1973), 2i4h (1662-1973), 2i4g (1662-1973), 2i4e (1662-1973), 2i3u (1662-1973), 2i3r (1662-1973), 2h04 (1662-1973), 2h02 (1662-1973), 2hc2 (1676-1965), 2hc1 (1676-1965), 2ahs (1686-1971), 2h03 (A=1676-1970)
OPM none
Complexes none
Interactions

ALK, Complex: ALK:PTPRB

CADH2, Complex: PTPRB:CADH2, PubMed

CADH5, Complex: PTPRB:CADH5, PubMed

CNTP1, Complex: PTPRB:CNTP1, PubMed

EGFR, Complex: EGFR:PTPRB, PubMed

EPOR, Complex: EPOR:PTPRB

ERBB2, Complex: ERBB2:PTPRB, PubMed

GHR, Complex: PTPRB:GHR, PubMed

INSR, Complex: INSR:PTPRB

JAM1, Complex: JAM1:PTPRB, PubMed

MET, Complex: MET:PTPRB, PubMed

NRCAM, Complex: NRCAM:PTPRB, PubMed

NTRK1, Complex: NTRK1:PTPRB

PGFRB, Complex: PGFRB:PTPRB

TIE2, Complex: PTPRB:TIE2, PubMed

VGFR1, Complex: VGFR1:PTPRB, PubMed

Domains

AA: 24-103, PDBID: 1CN4, Subunit B, Seq Identity:31%, Fibronectin type III domain

AA: 112-194, PDBID: 1QR4, Subunit B, Seq Identity:30%, Fibronectin type III domain

AA: 290-368, PDBID: 1TDQ, Subunit A, Seq Identity:34%, Fibronectin type III domain

AA: 378-460, PDBID: 1QR4, Subunit B, Seq Identity:30%, Fibronectin type III domain

AA: 468-547, PDBID: 1TDQ, Subunit A, Seq Identity:34%, Fibronectin type III domain

AA: 555-633, PDBID: 1FNF, Subunit A, Seq Identity:30%, Fibronectin type III domain

AA: 644-725, PDBID: 1QR4, Subunit B, Seq Identity:29%, Fibronectin type III domain

AA: 732-812, PDBID: 1QR4, Subunit B, Seq Identity:30%, Fibronectin type III domain

AA: 819-899, PDBID: 2H41, Subunit A, Seq Identity:28%, Fibronectin type III domain

AA: 908-986, PDBID: 1QR4, Subunit B, Seq Identity:34%, Fibronectin type III domain

AA: 996-1077, PDBID: 1TDQ, Subunit A, Seq Identity:28%, Fibronectin type III domain

AA: 1086-1165, PDBID: 1FNF, Subunit A, Seq Identity:29%, Fibronectin type III domain

AA: 1174-1252, PDBID: 2CUI, Subunit A, Seq Identity:30%, Fibronectin type III domain

AA: 1262-1344, PDBID: 1QR4, Subunit B, Seq Identity:25%, Fibronectin type III domain

AA: 1356-1435, PDBID: 1FNH, Subunit A, Seq Identity:27%, Fibronectin type III domain

AA: 1727-1962, PDBID: 2AHS, Subunit A, Seq Identity:100%, Protein-tyrosine phosphatase

UniProt annotation for PTPRB_HUMAN » Receptor-type tyrosine-protein phosphatase beta
FUNCTION: Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce dephosphorylation of TEK/TIE2, CDH5/VE-cadherin and KDR/VEGFR-2. Regulates angiopoietin-TIE2 signaling in endothelial cells. Acts as a negative regulator of TIE2, and controls TIE2 driven endothelial cell proliferation, which in turn affects blood vessel remodeling during embryonic development and determines blood vessel size during perinatal growth. Essential for the maintenance of endothelial cell contact integrity and for the adhesive function of VE-cadherin in endothelial cells and this requires the presence of plakoglobin (By similarity).

CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein tyrosine + phosphate.

SUBUNIT: Monomer. Interacts with TEK. Interacts via fibronectin type-III 17 domain with CDH5 (By similarity).

INDUCTION: Up-regulated by hypoxia.

UniProt features for PTPRB_HUMAN » Receptor-type tyrosine-protein phosphatase beta
SIGNAL 1 22 Potential.
CHAIN 23 1997 Receptor-type tyrosine-protein phosphatase beta.
DOMAIN 23 108 Fibronectin type-III 1.
DOMAIN 110 201 Fibronectin type-III 2.
DOMAIN 203 288 Fibronectin type-III 3.
DOMAIN 289 375 Fibronectin type-III 4.
DOMAIN 377 465 Fibronectin type-III 5.
DOMAIN 467 552 Fibronectin type-III 6.
DOMAIN 554 641 Fibronectin type-III 7.
DOMAIN 643 730 Fibronectin type-III 8.
DOMAIN 731 817 Fibronectin type-III 9.
DOMAIN 819 906 Fibronectin type-III 10.
DOMAIN 907 993 Fibronectin type-III 11.
DOMAIN 995 1083 Fibronectin type-III 12.
DOMAIN 1085 1172 Fibronectin type-III 13.
DOMAIN 1173 1260 Fibronectin type-III 14.
DOMAIN 1261 1353 Fibronectin type-III 15.
DOMAIN 1355 1443 Fibronectin type-III 16.
DOMAIN 1448 1550 Fibronectin type-III 17.
DOMAIN 1703 1963 Tyrosine-protein phosphatase.
REGION 1904 1910 Substrate binding (By similarity).
ACT_SITE 1904 1904 Phosphocysteine intermediate.
Amino Acid Sequence for PTPRB_HUMAN » Receptor-type tyrosine-protein phosphatase beta
MLSHGAGLAL WITLSLLQTG LAEPERCNFT LAESKASSHS VSIQWRILGS PCNFSLIYSS DTLGAALCPT FRIDNTTYGC NLQDLQAGTI YNFKIISLDE ERTVVLQTDP LPPARFGVSK EKTTSTGLHV WWTPSSGKVT SYEVQLFDEN NQKIQGVQIQ ESTSWNEYTF FNLTAGSKYN IAITAVSGGK RSFSVYTNGS TVPSPVKDIG ISTKANSLLI SWSHGSGNVE RYRLMLMDKG ILVHGGVVDK HATSYAFHGL SPGYLYNLTV MTEAAGLQNY RWKLVRTAPM EVSNLKVTND GSLTSLKVKW QRPPGNVDSY NITLSHKGTI KESRVLAPWI TETHFKELVP GRLYQVTVSC VSGELSAQKM AVGRTFPDKV ANLEANNNGR MRSLVVSWSP PAGDWEQYRI LLFNDSVVLL NITVGKEETQ YVMDDTGLVP GRQYEVEVIV ESGNLKNSER CQGRTVPLAV LQLRVKHANE TSLSIMWQTP VAEWEKYIIS LADRDLLLIH KSLSKDAKEF TFTDLVPGRK YMATVTSISG DLKNSSSVKG RTVPAQVTDL HVANQGMTSS LFTNWTQAQG DVEFYQVLLI HENVVIKNES ISSETSRYSF HSLKSGSLYS VVVTTVSGGI SSRQVVVEGR TVPSSVSGVT VNNSGRNDYL SVSWLVAPGD VDNYEVTLSH DGKVVQSLVI AKSVRECSFS SLTPGRLYTV TITTRSGKYE NHSFSQERTV PDKVQGVSVS NSARSDYLRV SWVHATGDFD HYEVTIKNKN NFIQTKSIPK SENECVFVQL VPGRLYSVTV TTKSGQYEAN EQGNGRTIPE PVKDLTLRNR STEDLHVTWS GANGDVDQYE IQLLFNDMKV FPPFHLVNTA TEYRFTSLTP GRQYKILVLT ISGDVQQSAF IEGFTVPSAV KNIHISPNGA TDSLTVNWTP GGGDVDSYTV SAFRHSQKVD SQTIPKHVFE HTFHRLEAGE QYQIMIASVS GSLKNQINVV GRTVPASVQG VIADNAYSSY SLIVSWQKAA GVAERYDILL LTENGILLRN TSEPATTKQH KFEDLTPGKK YKIQILTVSG GLFSKEAQTE GRTVPAAVTD LRITENSTRH LSFRWTASEG ELSWYNIFLY NPDGNLQERA QVDPLVQSFS FQNLLQGRMY KMVIVTHSGE LSNESFIFGR TVPASVSHLR GSNRNTTDSL WFNWSPASGD FDFYELILYN PNGTKKENWK DKDLTEWRFQ GLVPGRKYVL WVVTHSGDLS NKVTAESRTA PSPPSLMSFA DIANTSLAIT WKGPPDWTDY NDFELQWLPR DALTVFNPYN NRKSEGRIVY GLRPGRSYQF NVKTVSGDSW KTYSKPIFGS VRTKPDKIQN LHCRPQNSTA IACSWIPPDS DFDGYSIECR KMDTQEVEFS RKLEKEKSLL NIMMLVPHKR YLVSIKVQSA GMTSEVVEDS TITMIDRPPP PPPHIRVNEK DVLISKSSIN FTVNCSWFSD TNGAVKYFTV VVREADGSDE LKPEQQHPLP SYLEYRHNAS IRVYQTNYFA SKCAENPNSN SKSFNIKLGA EMESLGGKRD PTQQKFCDGP LKPHTAYRIS IRAFTQLFDE DLKEFTKPLY SDTFFSLPIT TESEPLFGAI EGVSAGLFLI GMLVAVVALL ICRQKVSHGR ERPSARLSIR RDRPLSVHLN LGQKGNRKTS CPIKINQFEG HFMKLQADSN YLLSKEYEEL KDVGRNQSCD IALLPENRGK NRYNNILPYD ATRVKLSNVD DDPCSDYINA SYIPGNNFRR EYIVTQGPLP GTKDDFWKMV WEQNVHNIVM VTQCVEKGRV KCDHYWPADQ DSLYYGDLIL QMLSESVLPE WTIREFKICG EEQLDAHRLI RHFHYTVWPD HGVPETTQSL IQFVRTVRDY INRSPGAGPT VVHCSAGVGR TGTFIALDRI LQQLDSKDSV DIYGAVHDLR LHRVHMVQTE CQYVYLHQCV RDVLRARKLR SEQENPLFPI YENVNPEYHR DPVYSRH